On Monday morning, Orphazyme was forced to announce that the firm had not seen the results from the phase II/III trial with arimoclomol as treatment for inclusion body myositis (IBM) for which the company management had hoped.
The study had no safety issues, but the company informs that it neither met its primary, nor its secondary endpoints.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.